Anbio Biotechnology (NNNN) Beginning Cash Balance (2023 - 2024)
Anbio Biotechnology (NNNN) posted Beginning Cash Balance of $9.7 million for Q4 2024, up 36.41% on a QoQ basis from $7.1 million in Q4 2023, and up 36.41% year-over-year from $7.1 million in Q1 2024.
Powered by 
Analysis
Anbio Biotechnology (NNNN) Beginning Cash Balance (2023 - 2024) Analysis & Trends
Anbio Biotechnology has reported Beginning Cash Balance for 2 years, with the latest figure at $9.7 million in Q4 2024.
- On a quarterly basis, Beginning Cash Balance rose 36.41% year-over-year to $9.7 million in Q4 2024; TTM through Dec 2024 was $9.7 million, a 36.41% increase from a year earlier, with the FY2024 full-year figure at $9.7 million, up 36.41% from the prior year.
- Beginning Cash Balance was $9.7 million for Q4 2024 at Anbio Biotechnology, up from $7.1 million in the prior quarter.
- The five-year high for Beginning Cash Balance was $9.7 million in Q4 2024, with the low at $7.1 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 28.97 Bn | 27.09 Bn | 2.18 Bn |
| 2 | Lantheus Holdings | 6.56 Bn | 5.97 Bn | 241.86 Mn |
| 3 | Heartflow | 4.40 Bn | 4.03 Bn | 53.19 Mn |
| 4 | Neogen | 2.83 Bn | 2.64 Bn | 107.80 Mn |
| 5 | Butterfly Network | 1.88 Bn | 1.75 Bn | 23.29 Mn |
| 6 | Ceribell | 931.50 Mn | 802.24 Mn | 25.94 Mn |
| 7 | Varex Imaging | 779.32 Mn | 694.02 Mn | 76.70 Mn |
| 8 | Anbio Biotechnology | 755.43 Mn | 743.53 Mn | - |
| 9 | QuidelOrtho | 725.35 Mn | 601.95 Mn | - |
| 10 | Prenetics Global | 339.92 Mn | 280.78 Mn | 30.20 Mn |